Marimed (MRMD) Preferred Stock Liabilities (2020 - 2026)

Marimed (MRMD) has 7 years of Preferred Stock Liabilities data on file, last reported at $6.9 million in Q1 2026.

• Preferred Stock Liabilities for Q1 2026 came in at $6.9 million, down 52.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.9 million (down 52.92% YoY), and the FY2025 annual result was $14.7 million, down 22.5% from the prior year.
• Preferred Stock Liabilities fell to $6.9 million in Q1 2026 per MRMD's latest filing, from $14.7 million in the prior quarter.
• Over five years, Preferred Stock Liabilities peaked at $37.7 million in Q1 2022 and troughed at $6.9 million in Q1 2026.
• A 5-year average of $23.0 million and a median of $19.0 million in 2023 frame the typical range for Preferred Stock Liabilities.
• The sharpest annual moves came in 2022 and 2026: Preferred Stock Liabilities changed 0.0% in 2022, then tumbled 52.92% in 2026.
• A 5-year view of Preferred Stock Liabilities shows it stood at $37.7 million in 2022, then slumped by 49.64% to $19.0 million in 2023, then changed by 0.0% to $19.0 million in 2024, then dropped by 22.5% to $14.7 million in 2025, then sank by 52.92% to $6.9 million in 2026.
• Business Quant data shows MRMD's Preferred Stock Liabilities at $6.9 million in Q1 2026, $14.7 million in Q4 2025, and $14.7 million in Q3 2025.